The five LMS groups were further analyzed for potential enrichment with key genomic markers of CRC beyond MSI status, including mutations of TP53, KRAS, NRAS, and BRAFV600E (Fig. 3b). This evidence concerns the gene KRAS and colorectal carcinoma.